Page 3 - Cyte Corporation News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Cyte corporation. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Cyte Corporation Today - Breaking & Trending Today

OncoCyte (NASDAQ:OCX) Given New $4.25 Price Target at Needham & Company LLC

OncoCyte (NASDAQ:OCX – Get Free Report) had its price objective boosted by equities researchers at Needham & Company LLC from $3.60 to $4.25 in a note issued to investors on Wednesday, Benzinga reports. The firm currently has a “buy” rating on the stock. Needham & Company LLC’s price target points to a potential upside of […] ....

United States , Andrew Arno , Oncocyte Corporation , Needham Company , Oncocyte Company Profile , Get Free Report , Broadwood Partners , Director Andrew Arno , Cyte Corporation , Oncocyte Daily , Nasdaq Ocx , Boost Price Target , Needham Company Llc ,

OncoCyte (NASDAQ:OCX) Given New $4.25 Price Target at Needham & Company LLC

OncoCyte (NASDAQ:OCX) Given New $4.25 Price Target at Needham & Company LLC
themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.

United States , Andrew Arno , Needham Company , Oncocyte Corporation , Oncocyte Company Profile , Get Free Report , Broadwood Partners , Director Andrew Arno , Cyte Corporation , Oncocyte Daily ,

OncoCyte's (OCX) Equal Weight Rating Reiterated at Stephens

Stephens reaffirmed their equal weight rating on shares of OncoCyte (NASDAQ:OCX – Free Report) in a research report released on Wednesday, Benzinga reports. They currently have a $4.00 price target on the stock. Several other research analysts have also commented on OCX. Benchmark reaffirmed a speculative buy rating and set a $5.00 price objective on […] ....

United States , Andrew Arno , Goldman Sachs Group Inc , Oncocyte Corporation , Cubist Systematic Strategies , Oncocyte Company Profile , Vanguard Group Inc , Securities Exchange Commission , Raymond James Financial Services Advisors Inc , Free Report , Cyte Stock Down , Director Andrew Arno , Exchange Commission , Broadwood Partners , James Financial Services Advisors , Sachs Group , Get Free Report , Cyte Corporation , Oncocyte Daily , Nasdaq Ocx , Reiterated Rating ,

StockNews.com Initiates Coverage on OncoCyte (NASDAQ:OCX)

StockNews.com initiated coverage on shares of OncoCyte (NASDAQ:OCX – Free Report) in a report released on Sunday. The firm issued a sell rating on the stock. OncoCyte Trading Up 0.3 % NASDAQ:OCX opened at $2.94 on Friday. OncoCyte has a one year low of $2.08 and a one year high of $7.20. The company has […] ....

United States , Cubist Systematic Strategies , Oncocyte Corporation , Raymond James Financial Services Advisors Inc , Vanguard Group Inc , Goldman Sachs Group Inc , Free Report , James Financial Services Advisors , Sachs Group , Get Free Report , Cyte Corporation , Oncocyte Daily , Nasdaq Ocx , Initiated Coverage , Stocknews Com ,

StockNews.com Initiates Coverage on OncoCyte (NASDAQ:OCX)

Investment analysts at StockNews.com assumed coverage on shares of OncoCyte (NASDAQ:OCX – Get Free Report) in a note issued to investors on Sunday. The firm set a “sell” rating on the stock. OncoCyte Stock Performance OCX stock opened at $2.98 on Friday. OncoCyte has a one year low of $2.08 and a one year high […] ....

United States , Cubist Systematic Strategies , Renaissance Technologies , Oncocyte Company Profile , Raymond James Financial Services Advisors Inc , Balyasny Asset Management , Oncocyte Corporation , Get Free Report , Systematic Strategies , James Financial Services Advisors , Asset Management , Cyte Corporation , Oncocyte Daily , Nasdaq Ocx , Initiated Coverage , Stocknews Com ,